Extrahepatic Cholangiocarcinoma Clinical Trials

4 recruiting

Extrahepatic Cholangiocarcinoma Trials at a Glance

6 actively recruiting trials for extrahepatic cholangiocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Aichi, Bonn, and Busan. Lead sponsors running extrahepatic cholangiocarcinoma studies include Aichi Medical University, First People's Hospital of Hangzhou, and Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

Browse extrahepatic cholangiocarcinoma trials by phase

Treatments under study

About Extrahepatic Cholangiocarcinoma Clinical Trials

Looking for clinical trials for Extrahepatic Cholangiocarcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Extrahepatic Cholangiocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Extrahepatic Cholangiocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting
Not Applicable

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma
Aichi Medical University120 enrolled8 locationsNCT07235007
Recruiting
Phase 2

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic CholangiocarcinomaUnresectable Perihilar or Ductal CCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest42 enrolled10 locationsNCT06440993
Recruiting

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

ctDNAGall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)+3 more
Yingbin Liu, MD, PhD, FACS1,800 enrolled1 locationNCT07176962
Recruiting

Bile Omics for Diagnosing Indeterminate Biliary Strictures

Pancreatic CancerCholangiocarcinomaGallbladder Cancer and Extrahepatic Cholangiocarcinoma+2 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine260 enrolled1 locationNCT07007832
Recruiting
Not Applicable

Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma

Bile Duct CancerExtrahepatic Cholangiocarcinoma
First People's Hospital of Hangzhou70 enrolled1 locationNCT05519319